IGM Biosciences (NASDAQ:IGMS) Shares Gap Up to $18.76
IGM Biosciences (NASDAQ:IGMS) Shares Gap Up to $18.76
Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Rating) gapped up before the market opened on Tuesday . The stock had previously closed at $18.76, but opened at $20.16. IGM Biosciences shares last traded at $20.10, with a volume of 498 shares trading hands.
週二開盤前，IGM Biosciences，Inc.(納斯達克代碼：IGMS-GET Rating)的股價大幅上漲。該股此前收盤報18.76美元，開盤報20.16美元。IGM Biosciences的股票最新報20.10美元，成交量為498股。
Analysts Set New Price Targets
分析師設定新的價格目標
IGMS has been the topic of several research analyst reports. Robert W. Baird decreased their price objective on shares of IGM Biosciences from $46.00 to $31.00 and set an "outperform" rating on the stock in a research note on Wednesday, June 1st. Bank of America began coverage on shares of IGM Biosciences in a report on Monday, August 29th. They set a "buy" rating and a $34.00 price objective on the stock. Guggenheim reduced their target price on shares of IGM Biosciences to $40.00 in a research report on Monday, August 15th. Finally, Truist Financial dropped their price objective on shares of IGM Biosciences from $74.00 to $37.00 and set a "buy" rating for the company in a research report on Tuesday, August 23rd. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $53.00.
IGMS一直是幾份研究分析師報告的主題。羅伯特·W·貝爾德在6月1日星期三的一份研究報告中將IGM Biosciences的股票目標價從46.00美元下調至31.00美元，並對該股設定了“跑贏大盤”的評級。美國銀行在8月29日星期一的一份報告中開始報道IGM Biosciences的股票。他們為該股設定了“買入”評級和34.00美元的目標價。古根海姆在8月15日星期一的一份研究報告中將IGM Biosciences的股票目標價下調至40.00美元。最後，Truist Financial在8月23日(星期二)的一份研究報告中將IGM Biosciences的股票目標價從74.00美元下調至37.00美元，併為該公司設定了“買入”評級。兩名投資分析師對該股的評級為持有，七名分析師對該公司的評級為買入。根據MarketBeat.com的數據，該公司目前的平均評級為“中等買入”，平均目標價為53.00美元。
IGM Biosciences Stock Performance
IGM Bioscions股票表現
The firm's 50-day simple moving average is $20.28 and its 200 day simple moving average is $18.81. The company has a market cap of $839.12 million, a P/E ratio of -3.54 and a beta of -0.32.
該公司的50日簡單移動均線切入位為20.28美元，200日簡單移動均線切入位為18.81美元。該公司市值為8.3912億美元，市盈率為-3.54，貝塔係數為-0.32。
Insider Activity at IGM Biosciences
IGM生物科學公司的內部活動
In related news, insider Bruce Keyt sold 8,700 shares of the business's stock in a transaction that occurred on Friday, August 19th. The shares were sold at an average price of $22.82, for a total transaction of $198,534.00. Following the completion of the transaction, the insider now owns 39,489 shares in the company, valued at $901,138.98. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 30,000 shares of company stock worth $622,107 in the last ninety days. Company insiders own 55.96% of the company's stock.
在相關新聞中，內部人士Bruce KEYT在8月19日星期五的一筆交易中出售了8700股該公司的股票。這些股票以22.82美元的平均價格出售，總成交金額為198,534.00美元。交易完成後，這位內部人士現在擁有該公司39,489股，價值901,138.98美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可以通過美國證券交易委員會網站。在過去的90天裏，內部人士賣出了30,000股公司股票，價值622,107美元。公司內部人士持有該公司55.96%的股份。
Hedge Funds Weigh In On IGM Biosciences
對衝基金參與IGM生物科學
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Hong Kong Ltd bought a new stake in shares of IGM Biosciences in the 4th quarter valued at $34,000. Amalgamated Bank bought a new stake in shares of IGM Biosciences in the first quarter worth about $36,000. Captrust Financial Advisors acquired a new stake in shares of IGM Biosciences during the second quarter worth about $50,000. US Bancorp DE lifted its holdings in shares of IGM Biosciences by 608.4% during the 1st quarter. US Bancorp DE now owns 2,437 shares of the company's stock valued at $65,000 after purchasing an additional 2,093 shares in the last quarter. Finally, American International Group Inc. grew its position in shares of IGM Biosciences by 15.0% in the 2nd quarter. American International Group Inc. now owns 4,684 shares of the company's stock valued at $84,000 after purchasing an additional 612 shares during the period. 41.20% of the stock is owned by institutional investors.
一些對衝基金和其他機構投資者最近對他們在該公司的頭寸進行了調整。Point72 Hong Kong Ltd在第四季度購買了IGM Biosciences的新股，價值34,000美元。合併銀行在第一季度購買了IGM Biosciences價值約3.6萬美元的新股。CapTrust Financial Advisors在第二季度收購了IGM Biosciences價值約5萬美元的新股。美國Bancorp DE在第一季度增持了IGM Biosciences的股票，增幅為608.4%。US Bancorp DE現在擁有2437股該公司股票，價值6.5萬美元，此前在上個季度又購買了2093股。最後，美國國際集團(AIG)在第二季度增持了IGM Biosciences股票15.0%。美國國際集團(American International Group Inc.)在此期間又購買了612股，目前持有該公司4,684股股票，價值8.4萬美元。41.20%的股份由機構投資者持有。
About IGM Biosciences
關於IGM生物科學
(Get Rating)
(獲取評級)
IGM Biosciences, Inc, a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL).
IGM生物科學公司是一家生物技術公司，開發用於治療癌症、傳染病、自身免疫性疾病和炎症性疾病的免疫球蛋白M(IgM)抗體。該公司的主要候選產品是IGM-2323，這是一種雙特異性IgM抗體，正處於第二階段臨牀試驗，用於治療復發/難治性B細胞非霍奇金淋巴瘤(NHL)患者。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on IGM Biosciences (IGMS)
- Build A Better Tech Portfolio With Jabil Inc.
- Autodesk Is A Mature Company Still Acting Like A Growth Stock
- Is There Value In These Growth Stocks?
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- MO Money: Why Altria Group Stock is Rallying
- 免費獲取StockNews.com關於IGM生物科學的研究報告(IGMS)
- 與捷普公司一起打造更好的技術產品組合。
- 歐特克是一家成熟的公司，仍是一隻成長型股票
- 這些成長型股票有價值嗎？
- MarketBeat Podcast，3只股票關注紐蒙特礦業、沃爾瑪、AMC
- Mo Money：奧馳亞集團股價為何上漲
Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受IGM《生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對IGM Biosciences和相關公司的最新新聞和分析師評級的每日簡明摘要。